株洲千金药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 每股分配比例 A 股每股现金红利0.36元 一、 通过分配方案的股东大会届次和日期 证券代码：600479 证券简称：千金药业 公告编号：2025-038 本次利润分配方案经公司2025 年 5 月 29 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 本次利润分配以方案实施前的公司总股本418,507,117股为基数，每股派发现金红利0.36 元（含税） ，共计派发现金红利150,662,562.12元。 三、 相关日期 | 股份类别 | 股权登记日 | | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | --- | | Ａ股 | 2025/7/24 | － | 2025/7/25 | 2025/7/25 | | 四 ...

2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 证券代码：600479 证券简称：千金药业 公告编号：2025-038 株洲千金药业股份有限公司 A 股每股现金红利0.36元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/7/24 | － | 2025/7/25 | 2025/7/25 | 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本418,507,117股为基数，每股派发现金红利0.36 元（含税），共计派发现金红利150,662,562.12元。 1. 发放年度：2024年年度 2. 分派对象： 三、 相关日期 差异化分红送转： 否 一、 通过分配方案的股东 ...

Core Insights - The first aid kit industry is experiencing significant growth due to increased safety awareness and the need for emergency preparedness in various settings such as schools, businesses, and homes [1][11] - The market size of China's first aid kit industry is projected to reach 708 million yuan in 2024, reflecting a year-on-year increase of 4.94% [1][11] - Government policies promoting safety and health have created a favorable environment for the first aid kit industry, making it an essential part of urban and rural development [1][11] Industry Overview - First aid kits are containers that store medical supplies and medications for initial emergency treatment before professional medical help arrives [3] - Different types of first aid kits serve various purposes, including outdoor, disaster, medical, and civilian kits, containing items like oxygen tanks, splints, blood pressure monitors, and dressings [3][7] Market Demand - The demand for first aid kits is increasing due to urbanization and faster-paced lifestyles, leading to a greater need for emergency response to minor injuries and health issues [1][11] - The household first aid kit market is also expanding, with its size projected to grow from 277 million yuan in 2016 to 425 million yuan in 2024, representing a compound annual growth rate of 5.50% [13] Competitive Landscape - The first aid kit industry is becoming more concentrated, with leading companies gaining advantages in market share, technological capabilities, and brand influence [15] - Key players in the industry include Blue Sail Medical, Jiangsu Southern Medicine, and Yunnan Baiyao, among others [15][16][18] Sales Channels - E-commerce platforms are increasingly important for first aid kit sales, benefiting from changing consumer shopping habits and the rapid development of online markets [9] - In 2024, China's e-commerce transaction volume is expected to reach 46.41 trillion yuan, marking a year-on-year increase of 3.90% [9] Future Trends - The market demand for first aid kits is expected to grow due to improvements in the medical emergency system, heightened public health awareness, and the frequency of various emergencies [20] - Future first aid kits may incorporate technologies like IoT and big data for remote monitoring and smart diagnostics, with personalized kits designed for specific demographics such as children and the elderly [20]

Core Viewpoint - The legal opinion letter from Hunan Qiyuan Law Firm confirms that Zhuzhou Qianjin Pharmaceutical Co., Ltd. has obtained the necessary approvals and authorizations for the repurchase and cancellation of certain restricted stocks under its 2021 incentive plan, in compliance with relevant laws and regulations [2][11][14] Group 1: Approval and Authorization - The company has completed the necessary procedures for the repurchase and cancellation of restricted stocks as part of its incentive plan [4][11] - The independent directors have expressed their agreement with the relevant proposals regarding the incentive plan [5][9] - The company has received approval from the Zhuzhou Municipal Government's State-owned Assets Supervision and Administration Commission for the implementation of the incentive plan [6][11] Group 2: Repurchase and Cancellation Details - The repurchase and cancellation are due to the failure to meet performance assessment requirements, specifically a revenue growth rate of at least 50% for the second release period and 75% for the third release period compared to 2020 [11][12][13] - A total of 5,490,000 shares will be repurchased and canceled, involving 121 individuals [12][13][14] - The repurchase is expected to be completed by July 10, 2025, with necessary filings to be made with the relevant authorities [13][14] Group 3: Compliance and Legal Opinion - The legal opinion asserts that the reasons, quantities, and arrangements for the repurchase and cancellation comply with the relevant management measures and regulations [11][14] - The company is required to fulfill its information disclosure obligations and handle the reduction of registered capital [14]

Core Viewpoint - The company, Zhuzhou Qianjin Pharmaceutical Co., Ltd., is implementing a repurchase and cancellation of restricted stock due to the failure to meet performance conditions for the second and third unlock periods of its 2021 restricted stock incentive plan [1][2]. Group 1: Repurchase and Cancellation Details - The repurchase involves a total of 5,490,000 shares of restricted stock, which will be canceled following the failure to meet the performance criteria set for the second and third unlock periods [2][4]. - The decision for the repurchase was approved by the 11th Supervisory Board meeting and does not require further approval from the shareholders' meeting [1][2]. - The company has established a dedicated securities account for the repurchase at the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, with the cancellation expected to be completed by July 10, 2025 [4][5]. Group 2: Impact on Share Structure - Following the repurchase and cancellation, the company's share structure will change as follows: - Restricted shares before: 5,490,000; after: 0 - Unrestricted shares before: 418,507,117; after: 418,507,117 - Total shares before: 423,997,117; after: 418,507,117 [5]. Group 3: Compliance and Legal Opinions - The company assures that the decision-making process and information disclosure comply with relevant laws and regulations, including the Management Measures for Equity Incentives of Listed Companies [4][5]. - The legal opinion from Hunan Qiyuan Law Firm confirms that the repurchase and cancellation comply with applicable laws and regulations, and the company will fulfill its information disclosure obligations [5][6].

株洲千金药业股份有限公司 关于限制性股票回购注销实施公告 证券代码：600479 证券简称：千金药业 公告编号：2025-037 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购注销原因：株洲千金药业股份有限公司（以下简称"公 司"）2021 年限制性股票激励计划第二个及第三个解除限售期解除限 售条件未成就，公司拟对所涉激励对象已获授但尚未解除限售的 5,490,000 股限制性股票予以回购注销。 本次回购注销股份的有关情况 | 回购股份数（股） | 注销股份数（股） | | 注销日期 | | | | --- | --- | --- | --- | --- | --- | | 5,490,000 | 5,490,000 | 2025 | 年 7 | 月 | 10 日 | 一、本次限制性股票回购注销的决策与信息披露 1.2025 年 4 月 25 日，公司召开第十一届董事会第十二次会议和 第十一届监事会第十一次会议，审议通过《关于公司 2021 年限制性 股票激励计划第二个及第三个解除限售期解除限售条件未成就 ...

湖南启元律师事务所 关于株洲千金药业股份有限公司 2021年限制性股票激励计划 致：株洲千金药业股份有限公司 湖南启元律师事务所（以下简称"本所"）接受株洲千金药业股份有限公司 （以下简称"公司"或"千金药业"）委托，担任千金药业 2021 年限制性股票 激励计划（以下简称"本次激励计划"）的专项法律顾问。 部分限制性股票回购注销实施情况的 法律意见书 湖南启元律师事务所 关于株洲千金药业股份有限公司 2021 年限制性股票激励计划 部分限制性股票回购注销实施情况的 法律意见书 本所根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市 公司股权激励管理办法》（以下简称"《管理办法》"）、《国有控股上市公司 (境内)实施股权激励试行办法》、《关于规范国有控股上市公司实施股权激励制 度有关问题的通知》等法律、法规和规范性文件以及《株洲千金药业股份有限公 司章程》，按照律师行业公认的业务标准、道德规范和勤勉尽责精神，现就公司 2021 年限制性股票激励计划部分限制性股票回购注销实施（以下简称"本次回 购注销"）相关事宜，出具本法律意见书。 为出具本《法律意见书》，本所特作如下声明： （一）本所依据我国法律 ...

Company Overview - Zhuzhou Qianjin Pharmaceutical Co., Ltd. primarily engages in the research, production, and sales of chemical synthetic raw materials and solid preparations, with key products including Valsartan capsules and other medications [3][5] - Qianjin Xiangjiang Pharmaceutical's nine centralized procurement varieties have seen sales growth exceeding 20% year-on-year, while Qianjin Xieli Pharmaceutical's product, Benazepril, has experienced over 30% sales growth [3][5] Revenue Analysis - The company has reported significant revenue from centralized procurement, with the revenue from centralized procurement increasing substantially over the reporting period [9][10] - For Qianjin Xiangjiang Pharmaceutical, the revenue from centralized procurement accounted for 57.09% in 2024, up from 7.50% in 2020, indicating a strong shift towards centralized procurement sales [9][10] - The average selling price for centralized procurement has decreased from 7.66 to 6.61, while the non-centralized procurement price has also seen a decline from 25.99 to 17.50 [9][10] Market Position and Competitive Landscape - The market for hypertension medications is projected to grow, with the number of hypertension patients in China expected to reach 400 million by 2030, driving demand for products like Valsartan [7][8] - Qianjin Xiangjiang holds approximately 3% market share in the Valsartan segment, while its market share in other products varies, indicating a competitive landscape with several key players [7][8] - The company benefits from a self-operated team and strong brand recognition, which enhances its market position against competitors [7][8] Product Development and Pipeline - The company has several products undergoing research and development, with a focus on expanding its portfolio in response to market needs [6][8] - The market for liver protection drugs, such as Silymarin, is expected to grow significantly, with Qianjin Xieli's market share projected to reach 40% by 2030 [8] Cost and Expense Management - The company has optimized its production processes, which is expected to enhance its cost management and pricing strategies in future centralized procurement rounds [8][9] - The gross profit margin for centralized procurement products has improved, reflecting better cost control and pricing strategies [9][10]

关于株洲千金药业股份有限公司 发行股份及支付现金购买资产暨关联交易 申请的审核问询函 独立财务顾问 签署日期：二〇二五年七月 6-1-1 上海证券交易所： 按照贵所下发的《关于株洲千金药业股份有限公司发行股份及支付现金购买 资产暨关联交易申请的审核问询函》(上证上审(并购重组)(2025)23 号)(以下简 称"审核问询函")的要求，株洲千金药业股份有限公司(以下简称"公司"、 "上市公司"或"千金药业")及相关中介机构就审核问询函所提问题进行了认 真讨论分析，并按照要求在《株洲千金药业股份有限公司发行股份及支付现金购 买资产并募集配套资金暨关联交易报告书(草案)(修订稿)》(以下简称"重组报 告书")中进行了补充披露，现将相关回复说明如下。 本审核问询函回复（以下简称"本回复"）中的报告期指 2022 年、2023 年、 2024 年；除此之外，如无特别说明，本回复所述的词语或简称与重组报告书中 "释义"所定义的词语或简称具有相关的含义。在本回复中，若合计数与各分项 数值相加之和在尾数上存在差异，均为四舍五入所致。 | 审核问询函所列问题 | 黑体(加粗) | | --- | --- | | 审核问询函所列 ...

目 录 | 一、关于标的公司业务………………………………………………第 | 1—41 | 页 | | --- | --- | --- | | 二、关于营业收入………………………………………………… | 第 41—71 | 页 | | 三、关于成本与费用………………………………………………第 | 71—104 | 页 | | 四、关于关联交易………………………………………………第 | 104—115 | 页 | | 五、关于其他……………………………………………………第 | 115—119 | 页 | 关于株洲千金药业股份有限公司 发行股份及支付现金购买资产暨关联交易 申请的审核问询函 之问询问题中有关财务事项的说明（修订稿） 天健函〔2025〕2-103 号 上海证券交易所： 由国投证券股份有限公司转来的《关于株洲千金药业股份有限公司发行股份 及支付现金购买资产暨关联交易申请的审核问询函》（上证上审（并购重组） 〔2025〕23 号，以下简称审核问询函）奉悉。我们已对审核问询函所提及的株 洲千金药业股份有限公司（以下简称千金药业公司或公司）关于问询问题中有关 财务事项进行了审慎核查，现汇报如下。（除另有标注外 ...